Skip to main content
. 2017 Feb 4;8(9):14283–14293. doi: 10.18632/oncotarget.15093

Figure 1. Melatonin treatment inhibits AngII-induced MMP2 and MMP9 expression.

Figure 1

A. MOVAS cells were pretreated with different concentration of melatonin (from 10 μM to 1 mM) for 4 hours followed by AngII treatment (1 μM) for 24 hours. Western blot was performed to detect MMP2 and MMP9 expression. B. MOVAS cells were pretreated with or without 100 μM melatonin followed by AngII treatment and western blot. C. and D. Quantitative analysis of MMP2 and MMP9 protein (C) and mRNA (D) levels in SMCs (n = 4). *p < 0.05 vs CTR group; #p < 0.05 vs AngII group. E. and F. Gelatin zymography of MMP2 and MMP9 activity (E) and their quantitative analysis (n = 4) (F). *p < 0.05 vs CTR group; #p < 0.05 vs AngII group.